Brodulamab Drug Aliquot | Anti-IL-17RA | Therapeutic Antibody

Aliquoted from the original drug | Now available for research use

Aliquots of the reference drug Brodalumab are now available as research consumables.

Brodalumab drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available.

The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.

Not looking for Brodalumab Reference Drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Kyntheum® / Brodalumab Reference Product

Drug nameKyntheum®
API typeMonoclonal antibody
Pharmacotherapeutic group
Immunosuppressants, Interleukin inhibitors.
ATC code
Target of antibody
General functionBrodalumab is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Brodalumab is a recombinant fully human monoclonal immunoglobulin IgG2 antibody that binds with high affinity to human IL-17RA and blocks the biological activities of the pro-inflammatory cytokines IL-17A, IL-17F, IL-17A/F heterodimer, IL-17C and IL-17E (also known as IL-25), resulting in inhibition of the inflammation and clinical symptoms associated with psoriasis.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)Elevated levels of IL-17A, IL-17C and IL-17F gene expression are found in psoriatic plaques. Elevated levels of expression of IL-12B and IL-23A, the genes for the two subunits of IL-23, an upstream activator of IL-17A and IL-17F expression, are also found in psoriatic plaques.
Original license holder
LEO Pharma A/S
Industriparken 55
DK-2750 Ballerup
Marketing authorisation numbers
EU/1/16/1155/001, EU/1/16/1155/002
Marketing authorisation holder
LEO Pharma A/S
Industriparken 55
DK-2750 Ballerup
Name of the manufacturer of the biological active substance
Immunex Rhode Island Corporation
40 Technology Way, West Greenwich,
Rhode Island, 02817
United States
Name and address of the manufacturer(s) responsible for batch releaseLaboratoires LEO
39 route de Chartres
28500 Vernouillet

LEO Pharma A/S
Industriparken 55
DK-2750 Ballerup
Max shelf life
4 years
Storage conditions
2°C – 8°C
List of excipients
Polysorbate 20
Water for injections

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.